Last reviewed · How we verify
Start adalimumab in monotherapy
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Crohn's disease, Ulcerative colitis, Rheumatoid arthritis.
At a glance
| Generic name | Start adalimumab in monotherapy |
|---|---|
| Also known as | begin humira in monotherapie in Early crohn disease patient |
| Sponsor | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in immune-mediated inflammatory diseases. By preventing TNF-α from binding to its receptors on immune cells, it suppresses the inflammatory cascade and reduces tissue damage. This mechanism is particularly effective in conditions driven by excessive TNF-α production, such as inflammatory bowel disease and rheumatoid arthritis.
Approved indications
- Crohn's disease
- Ulcerative colitis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Opportunistic infections
- Malignancy risk
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: